cancer therapy

T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Oncolytic viruses are cancer treatments that employ a natural or reprogrammed virus capable of targeting and killing malignant cells. They are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor...

LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...

It is needless to mention that Chemotherapy has been the most dependable cancer therapy. But, a new area of research shows the possibility of technology taking over the role of dominant cancer therapy in the future and in the event of which chemotherapy will be pushed to redundancy, as speculated. There is an ongoin...